I just ask the Senator from Minnesota if he has ever heard of the drug Daypro. It is a competing drug that had the same problems going through the FDA as Lodine, the same problems, the same delay. But in the 1996 omnibus appropriations bill, Daypro got an extension. I don't recall the Senator from Minnesota objecting to that extension, asking for that to be removed. But they got one, too. So what we have now is a competitive disadvantage. We have one company with a similar drug, a similar prescription, getting an extension and another drug with the same FDA problem not getting an extension. This is a health care bill. The Chair has ruled that it is within the scope of this bill. So I think what is going on here is, frankly, not a special interest, but simply a matter of fairness that we are trying to address.
Editor's note · Context
Discussing fairness in health care legislation regarding drug extensions during Senate debate.
Share
More from Rick Santorum
I think this puts Republican, particularly two senators in Georgia in a very tough bind to have a president, you know, having voted for the National Defense Authorization Act now, having to decide whether they're going to buck the…
I would make the argument that you have to look at Ohio too because Ohio's always very similar to Pennsylvania.
This is a moment where presidents matter. This is a moment when you -- as David said, in the last few days I think things have really change, attitudes and moods have changed in this country.
Joe Biden is not going to be successful. We're not going to bring this country together, if we continue the rhetoric at the level that we have seen.





